Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | PKM | P14618 | 1/20 | 0.80 |
| ▸ | UBE2N | P61088 | 1/20 | 0.80 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.80 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.80 |
| ▸ | APP | P05067 | 5/20 | 0.72 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | BCHE | P06276 | 5/20 | 0.72 |
| ▸ | ACHE | P22303 | 5/20 | 0.72 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.65 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.64 |
| ▸ | TCF7L2 | Q9NQB0 | 2/20 | 0.64 |
| ▸ | CASP6 | P55212 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3643618 | 0.99 | MAPT (0.83) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL3642835 | 0.93 | RAD52 (0.72) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL3636951 | 0.92 | RAD52 (0.69) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL12175837 | 0.91 | RAD52 (1.00) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL2580376 | 0.87 | RAD52 (0.76) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL2590399 | 0.87 | RAD52 (0.70) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL21567246 | 0.87 | BCHE (0.83) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL29490089 | 0.86 | CTNNB1 (0.77) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL22342962 | 0.86 | CTNNB1 (0.77) | RAD52MAPTKMT2ALMNAKDM4E | |
| SCHEMBL2583542 | 0.85 | RAD52 (0.82) | RAD52MAPTKMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | claimed |
| EP-2566480-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | California Institute of Technology (US) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011140527-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140527-A2 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | CALIFORNIA INSTITUTE OF TECHNOLOGY AND THE UNIVERSITY OF KANSAS (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | RAD52 1076/4885MAPT 4284/4885KMT2A 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.